В интернете кто-то неправ! Научные исследования спорных вопросов

13 Gilbert T. et al. The emergence of HIV/AIDS in the Americas and beyond // PNAS, 2007, Vol. 104, No. 47, 18566– 18570.

14 Пиневич А. В., Сироткин А. К., Гаврилова О. В., Потехин А. А. Вирусология: учебник. СПб.: Издательство Санкт-Петербургского университета, 2012. 432 с.

15 Ярилин А. А. Иммунология: учебник. М.: ГЭОТАР-Медиа, 2010. 752 с.

16 Атлас по медицинской микробиологии, вирусологии и иммунологии: Учебное пособие для студентов медицинских вузов / под ред. А. А. Воробьева, А. С. Быкова. М.: Медицинское информационное агентство, 2003. 236 с.

17 Doitsh G. et al. Cell death by pyroptosis drives CD4 T– cell depletion in HIV-1 infection // Nature, Jan. 2014, Vol. 505, 509–514.

18 The Durban Declaration // Nature, July 2000, Vol. 406, 15–16. Доступна по ссылке:v406/n6791/full/406015a0.html

19 De Clercq, E. The history of antiretrovirals: key discoveries over the past 25 years // Reviews in Medical Virology, Sep. 2009, Vol. 19, Issue 5, 287–299.

20 Volberding P. et al. Zidovudine in asymptomatic human immunodefciency virus infection. A controlled trial in persons with fewer than 50 °CD4-positive cells per cubic millimeter // New England Journal of Medicine, 1990, Vol. 322(14), 941–949.

21 Dournon E. et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex // Lancet, Dec. 1988, Vol. 332, No. 8623, 1297–1302.

22 Connor E. et al. Reduction of maternal-infant transmission of human immunodefciency virus type 1 with zidovu-dine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group // New England Journal of Medicine, Nov. 1994, 3; Vol. 331(18), 1173–1180.

23 Larder B, Kemp A. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) // Science, Dec. 1989: Vol. 246, No. 4934, 1155–1158.

24 Hammer S. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodefcien-cy virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team // New England Journal of Medicine, 1997, Sep. 11, Vol. 337(11), 725–733.

25 Gulick R. et al. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodefciency virus infection and prior antiretroviral therapy // New England Journal of Medicine, 1997, Vol. 337, 734–739.

26 Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies // Lancet, 2008, Vol. 372, 293–299.

27 Weller S., Davis K. Condom effectiveness in reducing heterosexual HIV transmission // The Cochrane Database of Systematic Reviews, 2002.

28 Townsend C. et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011 // AIDS, Apr. 2014, Vol. 28, Issue 7, 1049–1057.

29 Коалиция по готовности к лечению. Закупки АРВ-препаратов в 2014 году: хроника децентрализации. Результаты мониторинга закупок и предоставления АРВ-препаратов в РФ. Санкт-Петербург, 2015. Публикация доступна на сайте http://itpcru.org

30 Hutter G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation // New England Journal of Medicine, Feb. 2009, Vol. 360, 692–698.

31 Hutter G., Thiel E. Allogeneic transplantation of CCR5-defcient progenitor cells in a patient with HIV infection: An update after 3 years and the search for patient no. 2 // AIDS, Jan. 2011, Vol. 25, Issue 2, 273–274.

32 Yukl S. et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient // PLOS Pathogens, May 2013, Vol. 9(5), e1003347.

33 Brown T. I am the Berlin patient: A personal refection // AIDS Research and Human Retroviruses, Jan. 2015, Vol. 31, No. 1, 2–3.

34 Poropatich K., Sullivan D. Human immunodefciency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression // Journal of General Virology, February 2011, Vol. 92, No. 2, 247–268.

35 Saez-Cirion A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study // PLOS Pathogens, Mar. 2013, Vol. 9(3), e1003211.

36 Lehrman G., Hogue I. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study // Lancet, Aug. 2005, Vol. 366(9485), 549–555.

37 Tebas P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV // New England Journal of Medicine, 2014, Vol. 370, 901–910.